Welcome to our dedicated page for Quest Diagnostics news (Ticker: DGX), a resource for investors and traders seeking the latest updates and insights on Quest Diagnostics stock.
Quest Diagnostics Incorporated reports developments in diagnostic information services, laboratory testing and related healthcare data offerings. Company news commonly covers financial results, guidance, clinical testing activity, consumer access through questhealth.com and MyQuest, and advanced diagnostics such as Quest AD-Detect blood tests for Alzheimer’s disease and Haystack MRD ctDNA testing for oncology research.
Updates also include health system collaborations, Co-Lab Solutions activity, clinical trial and research partnerships, AI-enabled patient tools, board and executive appointments, dividends, share repurchases, debt financing and shareholder voting matters.
Summary not available.
Quest Diagnostics (NYSE: DGX) announced that its Board declared a quarterly cash dividend of $0.80 per share. The dividend is payable on January 28, 2026 to shareholders of record as of January 13, 2026. This provides a scheduled cash return to common shareholders and sets the key dates for eligibility and payment.
Quest Diagnostics (NYSE: DGX) announced that Sam Samad, executive vice president and chief financial officer, will speak at Citi's 2025 Global Healthcare Conference in Miami on Tuesday, December 2, 2025 at 3:15 p.m. ET.
The session will be a fireside chat with Q&A and will be webcast live on the company's investor relations page at ir.QuestDiagnostics.com. An archived webcast will be posted within 24 hours and will remain available through January 2, 2026.
Quest Diagnostics (NYSE: DGX) published a study showing two AD-Detect blood-test panels accurately identify Alzheimer’s pathology in symptomatic patients. In an intended-use cohort of 215 patients (46% amyloid PET-positive), both panels met a 91% sensitivity and 91% specificity threshold used for confirmatory testing. The three-biomarker panel (AB42/40 + p-tau217 + ApoE4) yielded PPV 88%, NPV 91% and a 10% indeterminate rate. The two-biomarker panel (AB42/40 + p-tau217) showed PPV 87%, NPV 91% and a 15% indeterminate rate. Quest launched the two-biomarker panel in April 2025 and plans a version of the three-biomarker test in Q1 2026.
Results meet recommended thresholds from Alzheimer's Association and CEOi for confirmatory blood-based tests, suggesting potential to reduce reliance on PET or CSF follow-up.
Quest Diagnostics (NYSE: DGX) reported Q3 2025 net revenues $2.82B (+13.1% vs. 2024) and reported diluted EPS $2.16 (+8.5%).
Adjusted diluted EPS was $2.60 (+13.0%). Year-to-date cash provided by operations was $1.4B (+63.1%).
The company raised full-year 2025 guidance: net revenues $10.96–11.00B, reported diluted EPS $8.58–8.66, adjusted diluted EPS $9.76–9.84, and cash from operations ~$1.8B.
Operational highlights include a lab services joint venture with Corewell Health (Co-Lab Solutions expected to scale to ~$1B annual revenue next year), acquisition of select Fresenius dialysis testing assets, consumer-health collaborations, FDA breakthrough designation for Haystack MRD, and published AD-Detect validation data.
WHOOP has launched WHOOP Advanced Labs, a revolutionary health feature combining blood testing with continuous wearable data monitoring. The service has garnered over 350,000 waitlist signups since May, demonstrating strong market demand.
Members can either upload existing bloodwork or schedule comprehensive testing through Quest Diagnostics (NYSE: DGX), with subscription options ranging from $199 for one test to $599 for four annual tests. The platform provides clinician-reviewed results, AI-powered coaching, and personalized recommendations by connecting biomarker data with 24/7 physiological monitoring.
This launch aligns with WHOOP's mission to add one billion healthy years to people's lives by creating a continuous feedback loop between clinical biomarkers and wearable data, helping members understand and improve their healthspan through actionable insights.
Quest Diagnostics (NYSE: DGX) has scheduled its Q3 2025 financial results release for October 21, 2025, before market opening. The company will host a conference call at 8:30 a.m. Eastern Time to discuss the results.
Participants can join via phone using specific dial-in numbers for U.S./Canada (888-455-0391) and international callers (773-756-0467) with passcode "7895081". A webcast will be available on the company's investor relations website, with replay access until November 5, 2025.
Guardant Health (NASDAQ: GH) and Quest Diagnostics (NYSE: DGX) have announced a strategic collaboration to expand access to Guardant's Shield™ blood-based colorectal cancer screening test across the United States. The Shield test, which is FDA-approved for average-risk adults aged 45 and older, will be available through Quest's extensive network of approximately 650,000 clinician and hospital accounts.
The partnership will enable physicians to order Shield directly through their existing Quest accounts and EHR systems. Patients will have access to blood draws at Quest's 2,000 service centers and 6,000 in-office phlebotomists. The test is expected to launch through Quest in Q1 2026. Shield is currently covered by Medicare and the Veterans Affairs Community Care Network.
Quest Diagnostics (NYSE: DGX) has announced a groundbreaking collaboration with Epic to enhance laboratory testing experiences across the United States. This first-of-its-kind partnership will serve as the foundation for Project Nova, Quest's initiative to improve customer-facing processes.
The implementation will leverage Epic's comprehensive Diagnostic Enterprise system, including Aura, Beaker Laboratory, Care Everywhere, MyChart, and Resolute Professional Billing & Claims across Quest's national laboratory network. The multi-year project aims to streamline account onboarding, lab ordering, results reporting, appointment scheduling, and billing services at Quest's 2,000 patient service centers.
Quest Diagnostics (NYSE:DGX) subsidiary Haystack Oncology announced a research collaboration with Rutgers Cancer Institute to evaluate Haystack MRD®, a ctDNA minimal residual disease test, for optimizing post-surgery treatment in stage II/III non-small cell lung cancer (NSCLC) patients.
The phase II study, dubbed MRD-PORT Trial (NCT06979661), will assess if residual tumor DNA detection post-surgery can guide radiation and systemic therapy decisions. The collaboration follows a 2023 study evaluating the test in early-stage triple-negative breast cancer patients.
Recent research published in NEJM demonstrated Haystack MRD's ability to identify clinical complete response 1.4 months faster than imaging tests. The test received FDA Breakthrough Device Designation in August 2025 for identifying MRD-positive stage II colorectal cancer patients.